NCT05697640View on ClinicalTrials.gov

Study to Investigate Improvement in Physical Function in SF-36 With Vericiguat Compared With Placebo in Participants With Post-COVID-19 Syndrome

PHASE2RecruitingINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

June 22, 2023

Primary Completion Date

October 1, 2025

Study Completion Date

December 31, 2025

Conditions
Post-COVID ME/CFS
Interventions
DRUG

Vericiguat Oral Tablet

The treatment period includes ten weeks of daily vericiguat or placebo intake (depending on randomization) and a 30-day follow-up period (no vericiguat/placebo intake).

Trial Locations (1)

10117

RECRUITING

Charité - Universitätsmedizin Berlin, Berlin

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

Charite University, Berlin, Germany

OTHER

NCT05697640 - Study to Investigate Improvement in Physical Function in SF-36 With Vericiguat Compared With Placebo in Participants With Post-COVID-19 Syndrome | Biotech Hunter | Biotech Hunter